Table 1.
Patient Characteristics at the Time of Index Percutaneous Coronary Intervention
| Full Cohort (n=2341) |
ABCD-GENE Score <10 (n=1836) | ABCD-GENE Score ≥10 (n=505) | p value for comparison of ABCD-GENE score <10 vs ≥10 | |
|---|---|---|---|---|
| Age, years | 64.2 ± 12.0 | 63.1 ± 11.7 | 68.2 ± 12.1 | <0.001 |
| Female sex | 817 (34.9) | 609 (33.2) | 208 (41.2) | 0.001 |
| Race | ||||
| White | 1733 (74.0) | 1357 (73.9) | 376 (74.5) | 0.968 |
| Black or African American | 470 (20.1) | 370 (20.2) | 100 (19.8) | |
| Other or Unknown Racec | 138 (5.9) | 109 (5.9) | 29 (5.7) | |
| BMI, kg/m 2 | 29.9 ± 6.6 | 28.9 ± 6.1 | 33.6 ± 7.0 | <0.001 |
| Current smoker | 672 (28.7) | 579 (31.5) | 93 (18.4) | <0.001 |
| PCI Indication a | ||||
| STEMI | 401 (17.1) | 342 (18.6) | 59 (11.7) | 0.17 |
| NSTEMI | 661 (28.2) | 505 (27.5) | 156 (30.9) | |
| UA | 539 (23.0) | 408 (22.2) | 131 (25.9) | |
| Stable CAD/Elective | 740 (31.6) | 581 (31.6) | 159 (31.5) | |
| PCI Strategy b | ||||
| Drug-eluting stent | 2009 (85.8) | 1587 (86.4) | 422 (83.6) | <0.001 |
| Bare metal stent | 261 (11.1) | 210 (11.4) | 51 (10.1) | |
| PTCA | 71 (3.0) | 39 (2.1) | 32 (6.3) | |
| Medical history | ||||
| Hypertension | 1953 (83.4) | 1490 (81.2) | 463 (91.7) | <0.001 |
| Dyslipidemia | 1540 (65.8) | 1167 (63.6) | 373 (73.9) | <0.001 |
| Prior MI | 616 (26.3) | 467 (25.4) | 149 (29.5) | 0.075 |
| Prior Revascularization | 1065 (45.5) | 797 (43.4) | 268 (53.1) | <0.001 |
| Prior Stent | 721 (30.8) | 539 (29.4) | 182 (36.0) | 0.005 |
| Prior CABG | 277 (11.8) | 204 (11.1) | 73 (14.5) | 0.047 |
| Prior PTCA | 67 (2.9) | 54 (2.9) | 13 (2.6) | 0.774 |
| Stroke/TIA | 287 (12.3) | 218 (11.9) | 69 (13.7) | 0.313 |
| PVD | 232 (9.9) | 176 (9.6) | 56 (11.1) | 0.359 |
| Heart failure | 387 (16.5) | 273 (14.9) | 114 (22.6) | <0.001 |
| Atrial fibrillation | 254 (10.9) | 178 (9.7) | 76 (15.0) | 0.001 |
| Gastrointestinal or intracranial hemorrhage | 68 (2.9) | 44 (2.4) | 24 (4.8) | 0.008 |
| Cancer | 120 (5.1) | 99 (5.4) | 21 (4.2) | 0.318 |
| Discharge medication | ||||
| Aspirin | 2288 (97.7) | 1799 (98.0) | 489 (96.8) | 0.17 |
| Statin | 2185 (93.3) | 1717 (93.5) | 468 (92.7) | 0.566 |
| β-blocker | 2007 (85.7) | 1575 (85.8) | 432 (85.5) | 0.948 |
| ACE inhibitor or ARB | 1555 (66.4) | 1213 (66.1) | 342 (67.7) | 0.519 |
| ARA | 99 (4.2) | 77 (4.2) | 22 (4.4) | 0.971 |
| Anticoagulant | 264 (11.3) | 176 (9.6) | 88 (17.4) | <0.001 |
| PPI | 763 (32.6) | 595 (32.4) | 168 (33.3) | 0.755 |
p value for comparison of primary PCI indication categories (i.e., myocardial infarction [STEMI/NSTEMI] vs. unstable angina or Stable CAD/Elective) between groups.
p value for comparison of PCI strategy (i.e., any stent type vs. PTCA) between groups.
Detailed breakdown includes patients of the following ancestries: American Indian or Alaska Native (n=29), Asian (n=14), mixed ancestry (n=2), Native Hawaiian or Other Pacific Islander (n=2), or unknown (n=91).
Data are presented as number (%) or mean ± SD.
ACE, angiotensin converting enzyme; ARA, aldosterone receptor antagonist; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting; IM, CYP2C19 intermediate metabolizer; MI, myocardial infarction; PCI, percutaneous coronary intervention; PPI, proton pump inhibitor; PTCA, percutaneous transluminal coronary angioplasty; PVD, peripheral vascular disease; STEMI, ST-segment elevation myocardial infarction; TIA, transient ischemic attack